Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05489614 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 6
- Study locations
NCT05489614: Completed Phase 1 study of Renal Impairment, sponsored by Amgen.
NCT05489614 is a Phase 1 study of Renal Impairment that has completed, run by Amgen. The registered enrollment target is 33 participants, roughly in line with the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target. The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05489614, a Phase 1 study of Renal Impairment, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
Conditions Studied
Interventions
- DRUG Olpasiran
Study Locations (6)
Florida
- Clinical Pharmacology Of Miami, LLC - Miami
- Advanced Pharma CR, LLC - Miami
- Orlando Clinical Research Center - Orlando
California
- Inland Empire Clinical Trials, LLC - Rialto
- CRSCA HC LLC, dba Creekside Post Acute - Yucaipa
Minnesota
- Nucleus Network - Minneapolis - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 1 |
What the finished NCT05489614 record still lists
NCT05489614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, roughly in line with the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Olpasiran is the first listed.
NCT05489614 lists 6 locations in 3 states (Florida, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05489614 about?
NCT05489614 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment". The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
What is the current status of trial NCT05489614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2022-09-13. Estimated completion is 2023-12-19.
What conditions does trial NCT05489614 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT05489614?
The interventions under investigation include: Olpasiran (DRUG).
Who is sponsoring clinical trial NCT05489614?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05489614 being conducted?
This trial has 6 study locations across California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05489614's enrollment target sits among peer trials
33 10th of 32 higher than 22 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI